Biochemical Effects Of Ribavirin (Antiviral) And Ddb (Hepato Protective) Drugs In Albino Rats

Soliman S. Ibrahim, Amr Shalaby and Mahmoud Rabeh
Zoology Department, Faculty of Science, Zagazig University

Abstract

The present investigation has been designed to through spot light on the efficiency of these two drugs in treatment of hepatitis patients. Cortisol, antigliadin (IgG) , total protein (TP) albumin (ALB) , Iron (Fe) , alanine aminotransferase (ALT) , aspartic aminotransferase (AST) and alkaline phosphatase (ALP) were determined in serum of normal mature male and female albino rats that injected intraperitoneally day after day with 1mg/kg body weight of each drug separately for 3 months. The cortisol level and ALP showed significant increase in each of ribavirin or DDB treated animals, while the IgG concentration in ribavirin treated animals increased significantly, but it is did not vary greatly from that of the control in DDB treated animals.

On the other hand both ribavirin and DDB treated male and female rats showed significant decrease in the ALT in serum while serum AST elicited non significant decrease in each of ribavirin and DDB treated male and female. With respect to serum TP and ALB levels the result showed significant decrease in ribavirin and non significant decrease in DDB treated male and female rats. Furthermore, the serum Fe level in ribavirin treated male and female rats increased significantly but it is did not vary greatly from that of the control in DDB treated animal.

Introduction

Ribavirin is a nucleoside analog that has demonstrated efficacy in treating viral disease as monotherapy [respiratory syncytail virus , lassa fever virus and foot and mouth disease virus infection] Hall et al., 1983 ; Wyde 1998; Robert et al., 2000 and Saad and Fawzy 2004)] and is used in combination with interferon – α to treated hepatitis C virus infection (McHutchinson et al., 1998 ; Davis et al., 1998 ; Reichard et al., 1998; Shane crotty et al. 2000 and Johnson et al., 2002).

Since the discovery of the broad – spectrum antiviral activity of ribavirin in 1972 (Sidwell et al., 1972), it has been suggested that the active from of ribavirin is the monophosphate, (RMP) (Streeter 1973). RMP inhibits inosine monophosphate dehydrogenase (IMPDH), causing a decrease in the intracellular concentration of guanosin triphosphate (GTP) (Smith and Kirkpatrick 1980 and Streeter 1973). This decrease potentially diminishes viral protein synthesis and limits replication of viral genomes. However, inhibition of IMPDH may not be sufficient for antiviral activity (Smith et al., 1984).

Tam et al., 1999 stated that ribavirin has multiple biologic properties that are favorable for treating viral diseases, it can directly inhibit the replication of many DNA and RNA viruses, it can also act as an immunomodulator and thus promote T- cell – mediated immunity against viral infection (Hultgren et al., 1998, Martin et al., 1998, Ning et al., 1998 and Tam et al., 1999).

The central focus of this effect of ribavirin is the augmentation of antiviral type 1 cytokine expression, gamma interferon and tumor necrosis factor alpha and concomitant supression of type 2 cytokine level by activated T cells in both human and murine system (Robert, et al., 2000) they also stated that ribavirin, alone or in combination with interferon - α, can lower serum alanine aminotransferase (ALT) level during the course of treatment of hepatitis C virus infection. Elevated serum ALT levels are a marker for liver damage and progressive hepatitis, and hence the
ribavirin- mediated lowering of ALT level is a distinct liver- specific effect of this nucleoside analog (Dusheiko et al., 1996). Robert et al., 2000 established that, the therapeutic use of ribavirin is restricted by is toxicological profile. Prolonged administration of ribavirin is frequently associated with anemia, whose severity correlates with dose level and which is reversible upon dose reduction or cessation of treatment. Also, Johnson et al., (2002) and Patrick et al., (2002) said that hemolytic anemia is a known side effect of ribavirin therapy. The mechanism is not firmly established. However, it is known that ribavirin is converted to its phosphorylated metabolites in all cell types but the conversion back to ribavirin through dephosphorylation occurs mainly in nucleated cells. Ohno Y. et al., 1998 concluded, plasma cortisol level increased after ribavirin and interferon-β injection, in parallel with plasma adrenocorticotropic hormone (ACTH) and serum growth hormone (GH) elevation. The main adverse effect of ribavirin had been discussed by Good man and Gilman (1996), they established that, the most important and expected adverse event associated with ribavirin was haemolysis but the anemia is mild and is accompanied by reticulocytosis and hyperbilirubinemia due to extravascular hemolysis. During chronic oral therapy, gastrointestinal and central nervous system adverse effects have been noted. A dry in mouth, increased thirst, anorexia, nausea and flatulence have been reported, in addition to fatigue unrelated to anemia. Central nervous system includes headache, insomnia, and irritability.

In addition to ribavirin as antivial drug DDB (dimethyl diphenyl bicarboxylate) a synthetic mimic of the natural product of schizandrin C, is used in china as a hepatoprotective agent to improve the liver functions of patients with hepatitis or under cancer chemotherapy (Alo Nag et al., 2001, Lu H and Li Y 2002, Chiu et al., 2003, Nakamura et al., 2003, Dutta - Bergman 2003 and Chang et al., 2004).

Huber et al., 2004 showed that, in vitro experiments with hepatocytes resulted in a significant decrease of hepatocellular ALT level in the DDB treated cells, suggesting, that DDB affects the synthesis and/or degradation of ALT in liver cells, and the normalization of ALT during DDB treatment does not indicate therapeutic efficacy. Also DDB was shown to protect against liver injury induced by chemical toxins such as carbon tetrachloride, thioacetamide and tetrahydroacridin (THA). Liy and Liy (2001) establish that, the alteration of mice body temperature, and the elevation of serum ALT, and mitochondria potential induced by THA were significantly inhibited by DDB treatment. On the other hand, the inhibiting effect of THA on mice hippocampus and cortex acetylcholines- terase in vivo and in vitro were not influenced by DDB treatment. In addition, DDB significantly increased the liver detoxicating ability and antagonized the mutagenicity of chemical carcinogens such as aflatoxin B (AFB). DDB (300 mg/ kg) pretreatment provided significant protection against AFB hepatotoxicity as evidenced by the decrease of AFB- elevated serum marker enzymes in rats. The results indicate that DDB protected rats against AFB hepatotoxicity by increasing the detoxifying metabolism of AFB in the liver (Lu H.,Li.Y. 2002).

Mammalian hepatitis B viruses encode an essential regulatory protein, termed X, which may also be implicated in liver cancer development associated with chronic infection (Francoise et al., 2002). Schek et al., (1991) reported that the feature of x protein is its rapid turnover. Francoise et al., (2002) establish a direct functional connection of X with the DDB heterodimer; (DDB1 and DDB2 which is a fraction of DDB after mutation). DDB1 markedly increase X stability which appears to directly protect X from the degradation process, whereas DDB2 acts on X stability in an indirect way involving the formation of the DDB heterodimer. There is a physical interaction occurring within the tripartite X-DDB complex mediate these effects through the modulation of proteasome- dependent degrading of X. They concluded from these observation that in the presence of an excess amount of DDB1 subunit, the proteasome pathway can
no longer operate on X protein, whereas further addition of the DDB2 subunit restores X targeting to proteasome-mediated degradation.

Wittschieben and Wood (2003) said that a group of recent publications contribute new insights concerning the role of the DNA damage-binding protein complex (DDB) in DNA repair, they concluded, it appear that DDB assists in nucleotide excision repair in chromatin. Also DDB has implicated in global genomic repair as well as in transcription of cell cycle genes. (Hwang et al., 1996, Hwang et al., 1999, Tang et al., 2000 and Alo Nag 2001).

Finally administration of 180 mg of ribavirin kg/day in mice was associated with lower food consumption, lower body weight and decrease in erythrocyte count, hemoglobin, hematocrit, leukocyte count and increased extramedullary hematopoesis in the spleen (Robert et al., 2000).

Materials And Methods

Ribavirin (L - B - D ribofuranosyl - 1H - 1, 2, 4 - Triazole - 3 carboxamide) is a synthetic nucleoside with antiviral activity, manufactured by OCTOBER PHARMA S.A.E. 6- October City Egypt.

DDB (dimethyl- 4, 4' - dimethyloxy - 5, 6, 5', 6' dimethylenedioxy biphenyl - 2, 2 - dicarboxylate) is a synthetic analogue of schizandrin C which is isolated from fructus schizandrae Chinese a traditional Chinese medicinal plant (Chang et al., 2004). It is manufactured by Beijing Union Pharmaceutical Factory Beijing P.R. China. 36 sprague - Dawley rats (18 males and 18 females) weighing 150- 170 grams from Veterinary Medicine Farm, Zagazig University were used in the present study.

Animal were allowed to accilate to laboratory conditions for 2 weeks before experimental manipulation, and fed ad libitum. They were divided into 6 groups (6 males in each of 1st, 3rd and 5th groups and 6 females in each of 2nd, 4th and 6th groups).

Animals of the 1st and 2nd groups were used as controls and were injected intraperitoneally with 1 ml/kg body weight of normal saline. Animals of the 3rd and 4th groups were injected intraperitoneally with 1mg/kg body weight of ribavirin. Rats of the 5th and 6th groups were injected intraperitoneally with 1 mg /kg body weight of DDB.

Treatments of all groups were carried out every other day for 3 months.

Individual blood samples were collected after decapitation and kept at room temperature for 2 hours, then centrifuged for 5 minutes at 5000 rpm. Collected sera were aliquoted and stored at -20 ºC until use.

The Active Cortisol RIA Dsl - 2100 kit provides materials from Diagnostic System Laboratories, Inc. Corporate Headquarters, 445 Medical Center, USA. It was determined according to (Schlaghecke et al., 1992).

Immunometric Enzyme Immunoassay for the quantitative determination of Anti-Gliding Antibodies of IgG class (ELISA) (Ralph 1988).

Kits from Biomerieux Lab Reagent and Products (France) were used for the determination of alanine aminotransferase (ALT), aspartate aminotransferase (AST) according to (Reitman and Frankel, 1957), alkaline phosphatase (ALP) according to (Roy, 1970), albumin (ALB) according to (Doumas et al., 1971) and serum total protein (Tp) according to (Lowry et al., 1951).

Serum iron was determined by Atomic Absorption Spectrophotometry (FMD3, Germany). Serum samples were deproteinized and diluted with deionized water. A standard iron solution was prepared to give 1 µg/dl and serially diluted to cover the range for iron standard curve (Dean et al., 1997).

Data were analyzed by student’s t-test for each statistical comparison according to (Selvin, 1996).

Results

* Cortisol level:

Table (1) and fig. (1) revealed that ribavirin and DDB were able to increase the level of cortisol significantly (P<0.001) in male rats by 36.5% and 25.0% and in
Biochemical Effects Of Ribavirin (Antiviral)

females by 17.5% and 10.3% above the control respectively.

* Anti-gliadin (IgG) level:
  Table (2) and fig (2) show a significant increase (P < 0.001) of IgG concentration by 12.5% and 23.67% above the control in ribavirin treated male and female rats respectively, whereas, no significant change was observed in this parameter in DDB treated male and female rats.

* Alkaline phosphatase (ALP) level:
  Table and fig. (3) represent the effect of ribavirin and DDB on serum ALP in male and female rats, it shows that ribavirin and DDB administration is accompanied by significant increase (P < 0.001) in ALP by 24.7% and 27.1% in ribavirin and by 17.8% and 21.2% above the control in DDB treated male and female rats respectively.

* Alanine aminotransferase (ALT):
  As shown in table (4) and Fig. (4) Ribavirin and DDB treatment caused significant decrease (P < 0.001) in serum ALT by 52.62% and 34.58% in ribavirin and by 37.38% and 21.62% in DDB treated male and female rats respectively.

* Aspartate aminotransferase (AST):
  Table (5) and fig. (5) demonstrate no significant change of serum AST following treatment of male and female rats with either ribavirin or DDB.

* Total protein (Tp):
  Total protein level in serum of male and female rats showed a significant decrease (P< 0.001) by 16.02% and 22.07% below the controls respectively, whereas no significance change in its level was recorded in DDB treated male and female rats respectively (Table 6 and Fig. 6).

* Albumin (ALB):
  Table (7) and Fig. (7) illustrate that the level of serum ALB in ribavirin treated male and female rats decreased significantly (P < 0.001) by 29.05% and 19.58% below the controls respectively, whereas, its level in serum of DDB treated male and female rats showed no significant change.

* Iron (Fe):
  Data presented in Table (8) and Fig. (8) show that serum Fe was increased significantly (P < 0.001) in ribavirin treated male and female rats by 29.40% and 33.41% above the controls respectively, but it was not affected significantly in DDB treated male and female rats.

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Ribavirin</th>
<th>DDB</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Male (mean ± S.E.)</strong></td>
<td>0.52 ± 0.02</td>
<td>0.71 ± 0.03*</td>
<td>0.65 ± 0.03*</td>
</tr>
<tr>
<td><strong>Female (mean ± S.E.)</strong></td>
<td>0.58 ± 0.05</td>
<td>0.68 ± 0.04*</td>
<td>0.64 ± 0.04*</td>
</tr>
<tr>
<td><strong>% of change</strong></td>
<td>+36.5%</td>
<td>+25.0%</td>
<td></td>
</tr>
<tr>
<td><strong>% of change</strong></td>
<td>+17.14%</td>
<td>+10.3%</td>
<td></td>
</tr>
</tbody>
</table>

* (P < 0.001)

Table and Fig. (1): Effect of intraperitoneal administration of ribavirin or DDB at the level of 1mg /kg body weight on serum cortisol concentration (µg/100 ml) in mature male and female albino rats. Each value represents the mean ± S.D. of 6 animals.
Table (2) and Fig. (2): Effect of intraperitoneal administration of ribavirin or DDB at the level of 1 mg/kg body weight on serum IgG concentration (IU/100 ml) in mature male and female albino rats. Each value represents the mean ± S.D. of 6 animals.

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Ribavirin</th>
<th>DDB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male (mean ± S.E.)</td>
<td>4.80 ± 0.24</td>
<td>5.40 ± 0.41*</td>
<td>5.00 ± 0.24 n.s.</td>
</tr>
<tr>
<td>% of change</td>
<td></td>
<td>+12.4%</td>
<td>4.16%</td>
</tr>
<tr>
<td>Female (mean ± S.E.)</td>
<td>4.52 ± 0.36</td>
<td>5.59 ± 0.38*</td>
<td>4.62 ± 0.27 n.s.</td>
</tr>
<tr>
<td>% of change</td>
<td></td>
<td>+23.67%</td>
<td>2.21%</td>
</tr>
</tbody>
</table>

* P <0.001  n.s. : Non – significance

Table (3) and Fig. (3): Effect of intraperitoneal administration of ribavirin or DDB at the level of 1 mg/kg body weight on serum ALP (IU/L) in mature male and female albino rats. Each value represents the means ± S.D. of 6 animals.

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Ribavirin</th>
<th>DDB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male (mean ± S.E.)</td>
<td>135.0 ± 11.5</td>
<td>168.3 ± 9.8*</td>
<td>159.0 ± 10.4*</td>
</tr>
<tr>
<td>% of change</td>
<td></td>
<td>24.7%</td>
<td>17.8%</td>
</tr>
<tr>
<td>Female (mean ± S.E.)</td>
<td>111.6 ± 7.2</td>
<td>141.8 ± 12.1*</td>
<td>135.3 ± 21.0*</td>
</tr>
<tr>
<td>% of change</td>
<td></td>
<td>27.1%</td>
<td>21.2%</td>
</tr>
</tbody>
</table>

* ( P < 0.001)

Table (4) and Fig. (4): Effect of intraperitoneal administration of ribavirin or DDB at the level of 1 mg/kg body weight on serum ALT (IU/L) in mature male and female albino rats. Each value represents the mean ± S.D. of 6 animals.

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Ribavirin</th>
<th>DDB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male (mean ± S.E.)</td>
<td>32.02 ± 2.01</td>
<td>15.17 ± 1.30*</td>
<td>20.05 ± 1.2*</td>
</tr>
<tr>
<td>% of change</td>
<td></td>
<td>-52.62%</td>
<td>-37.38%</td>
</tr>
<tr>
<td>Female (mean ± S.E.)</td>
<td>19.98 ± 1.85</td>
<td>13.07 ± 1.10*</td>
<td>15.66 ± 0.98</td>
</tr>
<tr>
<td>% of change</td>
<td></td>
<td>-34.58%</td>
<td>-21.62%</td>
</tr>
</tbody>
</table>

* ( P < 0.001)
Biochemical Effects Of Ribavirin (Antiviral) ———

n.s. Non-significance

Table and Fig. (5): Effect of intraperitoneal administration of ribavirin or DDB at the level of 1 mg/kg body weight on serum AST (IU/L) in mature male and female albino rats. Each value represents the mean ± S.D of 6 animals.

Table and Fig. (6): Effect of intraperitoneal administration of ribavirin or DDB at the level of 1 mg/kg body weight on serum TP level (g/dl) in mature male and female albino rats. Each value represents the mean ± S.D. of 6 animals.

Table (7): Effect of intraperitoneal administration of ribavirin or DDB at the level of 1mg/kg body weight on serum ALB level (g/dl) in mature male and female albino rats. Each value represents the mean ± S.D of 6 animals.
Table and Fig. (8): Effect of intraperitoneal administration of ribavirin or DDB at the level of 1 mg / kg body weight on serum Fe level (μg/dl) in mature male and female albino rats. Each value represents the mean ± S.D. of animals.

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Ribavirin</th>
<th>DDB</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Male</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(mean ± S.E.)</td>
<td>225.5±</td>
<td>291.8*</td>
<td>233.3*</td>
</tr>
<tr>
<td></td>
<td>15.3</td>
<td>19.2</td>
<td>12.8</td>
</tr>
<tr>
<td>% of change</td>
<td>-</td>
<td>+29.40%</td>
<td>+3.46%</td>
</tr>
<tr>
<td><strong>Female</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(mean ± S.E.)</td>
<td>210.4±</td>
<td>280.7±</td>
<td>215.2±</td>
</tr>
<tr>
<td></td>
<td>16.7</td>
<td>2.01*</td>
<td>15.3</td>
</tr>
<tr>
<td>% of change</td>
<td>-</td>
<td>+33.41%</td>
<td>+2.28%</td>
</tr>
</tbody>
</table>

* P<0.001       n.s Non- significance

**Discussion**

The present study includes the comparison between antiviral ribavirin and hepatoprotective DDB drugs, with respect to their biochemical effects associated with their clinical utility.

The result of cortisol hormone and ALP detection showed that, administration of the two drugs in both male and female rats produce significant increase (P<0.001) in serum cortisol and ALP concentration, this may be due to the inflammatory tissue response of the injected host. The inflammation stimulate the pituitary corticotropin hormone which stimulates the adrenal cortex to release the corticosteroids cortisone and cortisole as anti-inflammatory agents. This observation agree with the work of (Li et al., 1992, Hibi et al., 1997, Ohno et al., 1998, Montor et al., 1998, Johnson et al., 2002 and Marieke and Michael 2004).

They estabilised the antiviral hepatoprotective drugs as ribavirin, interferone-α and DDB stimulate the steroid hormones secretion and increase plasma cortisol levels.

In respect to antigliadin (IgG) the results showed significant increase (P<0.001) in its serum level of both male and female ribavirin treated animals, while it did not change in DDB treated animal. Thus ribavirin considered as antiviral drug and its mode of action could be summarized as the ribavirin resembles guanosine in its structure, which may exert an antiviral effect by reducing intracellular guanosine nucleotide pools, thereby inhibiting DNA and DNA synthesis. Also, in cells, ribavirin is phosphorylated by the cellular kinases and converted to ribavirin monophosphate (RMP) which inhibits inosine monophosphate dehydrogenase, an enzyme essential for the synthesis of guanosine triphosphate (GTP), which is essential component for DNA synthesis (Prescott et al., 2000, Johnson et al., 2002 and Saud and Fawzy, 2004), this is not concordant with DDB drug, but its hepatoprotective effect may be attributed to its regulation on enzymes involved in toxic agent metabolism and its protective effect against mitochondria injury caused by toxins. (Li Y and Li Y, 2001, Lu H and Li Y 2002 and Huber et al., 2004).

Furthermore, both drugs reduced serum ALT (significant decrease P<0.001), but not exhibited marked reduction in serum AST (non significance decrease). The same results reported by Chai – Jan Chang et al., (2000), he reported that ALT are more closely associated with hepatic infection than AST, and hepatic infection play an important role in the etiology of elevated ALT activity among drug abusers. Also, Johnson et al., (2002) stated, that mechanism of ribavirin action as it is a guanine analogue that is phosphorylated into its most active form, ribavirin-triphosphate. This compound competes with adenosine – triphosphate and guanine – triphosphate for binding sites at the polymerase, as well as inhibiting transferase enzymes, thus in patients receiving ribavirin monotherapy, serum ALT were reduced in a considerable proportion. These observations also agree with the work of Bizollon et al., (1999); Shane et al., (2000), Lise et al., (2001) and Pascal Veillon et al., (2003).

Moreover, Huber et al., (2004) said that in vitro experiments with hepatocytes resulted in a significant decrease of hepatocellular ALT in the DDB treated cells, suggesting that DDB affects the synthesis and / or degradation of ALT in liver cells. Unlike ALT, AST levels were not affected.

Similar results demonstrated by Li Y and Li Y (2001) and Lu H and Li Y (2002), they concluded, that the protective action of DDB
attributed to its regulation on enzymes and by increasing the detoxifying metabolism in the liver. Administration of ribavirin induced a significant decrease (P<0.001) of serum ALB and TP levels, while DDB treated animals showed non – significant decrease in ALB and TP level in serum. Ribavirin injection in rats or mice induces a behavioural pattern referred to as sickness behaviour which includes increased sleep, reduced locomotor activity decreased sucrose consumption, loss of appetite, weight loss and decreased social explor-ation, these symptoms resemble the vegetative symptoms of depression in human (De Sarro et al., 1990, Goodman and Gilman’s 1996, Robert et al., 2000 and Marieke et al. 2004). All these symptoms and long term ribavirin injection cause inflammation of liver cells which are responsible for albumin synthesis. Also, remarkable increase (P<0.001) in serum Fe concentration under the effect of ribavirin considered one of the side effects of ribavirin administration. Patrick et al., 2002 reported , that the most common adverse effect of ribavirin administration is reversible anemia caused by a combination of transient suppression of erythropoiesis and extravascular hemolysis from accumulation of phosphorylated drug in red blood cells, this hemolysis increase Fe level in serum , the same results were obtained by Thevenot et al., 1997 ,Robert et al., 2000), Shane et al., 2000, Lise et al., 2001 and Johnson et al., 2002. Finally, although, ribavirin has many side effects, it appears to be a pleiotropic agent with many intrinsic mechanisms that can influence its overall antiviral properties. Many investigators are favoring the immuno-omodulatory mechanism; although the possibility that ribavirin is a viral RNA mutagen is also gaining attention. Johnson et al. 2002 said, what we have learned so far is perhaps the tip of the iceberg for ribavirin . Wherease , DDB considered as one of hepatoprotective drugs and has not remarkable side effects as ribavirin , but little is known about DDB interaction within cellular content and further studies will be attended.

References

1. Alo Nag, Abhishek Datta, Kyung Yoo, Dihyenu Bhattacharyya, Amit Chakraborty, Xinhi Wang, Betty L. Slagle and Paradip Raychaudhuri (2001): DDB₂ induces nuclear accumula-


التأثيرات البيوكيميائية لعقاري الريبافيرين (مضاد فيروسي) وال دي دي بي (وقائي كيدي) في الجرذان البيضاء

سلام سيد احمد - عمرو شلبي - محمود رايه

قسم علم الحيوان - كلية العلوم - جامعة الزقازيق - جمهورية مصر العربية

برغم تعدد عوارض علاج الالتهابات الكبدية الفيروسية إلا أن هناك أبحاث عديدة تثبت فاعلية عقاري الريبافيرين وال دي دي بي والذي يعرف بالحبة الصفراء. ومن هنا كانت المحاولة في هذا البحث هو التعرف على بعض القياسات والتغيرات البيوكيميائية والأنزيمية في ذكور وإناث الجرذان السليمة عندما تعامل بهذه الأدوية. 

في هذا البحث تم حفظ بعض ذكور وإناث الجرذان البيضاء عقار الريبافيرين والبضع الآخر بعقار آل دي بي. وقد تم هذا الحفظ في الحالتين بجرعات ثابتة وممتلئة(1جم/ كيلو جرام) لمدة ثلاثة شهور في تجويف البطن. 

وكان العقاقر يستخدمان في علاج بعض حالات الالتهاب الكبدية الفيروسي. وفي هذا البحث يتم استخدامهما على الجرذان السليمة لبيان مدى الآثار الجانبية لهذه العقاقر على بعض القياسات البيوكيميائية والأنزيمية في مصل ذكور وإناث الجرذان البيضاء وقد أظهرت النتائج أن هناك زيادة ذات دلاله إحصائية في كل من هرمون الكورتيزول وإنزيم الفوسفات القلوي في مصل ذكور وإناث الجرذان بعد حقنها بالوقائي كيدي. 

وأوضحنا النتائج حقن الريبافيرين زيادة ملحوظة في مستوى IgG. كان من مصل الذكور والإناث بينما لم تكن الزيادة ملحوظة في حالة الحفظ بعقار آل دي بي، في كل الجنسين. وعلى عكس الزبادة كان هناك انخفاض ملحوظ في مستوى الإنزيم الكيدي ALT في مصل الذكور والإناث بينما كان الإنخفاض غير ملحوظ بالنسبة للإنزيم الكيدي AST وذلك بعد المعالجة طوي من العقاقر. أما بالنسبة لمستوى كلا من الألبومين والبروتين الكلي في مصل ذكور وإناث الجرذان فقد

أوضحنا النتائج انخفاض ملحوظ مع عقار الريبافيرين بينما كان الانخفاض غير ملحوظ مع عقار آل دي بي. كما سجل مستوى عصر الحديد في مصل ذكور وإناث الجرذان زيادة ملحوظة مع عقار الريبافيرين. أما بالنسبة لعقار آل دي بي فقد كانت الزبادة غير ملحوظة. ومن خلال هذه النتائج يتضح أن الآثار الجانبية لعقار الريبافيرين متعددة وأكثر تأثيراً على بعض القياسات الكيميائية والأنزيمية من عقار آل دي بي مع إثبات التأثير المناخي الإيجابي لكلا العقاقر.